by Anand Patadiya | Oct 2, 2024
Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced the appointment of Stephen Gorgol as chief financial officer. Mr. Gorgol, a proven financial leader within the biotech industry, joins...
by Anand Patadiya | Oct 2, 2024
Preliminary data of anchored canine IL-12 (cANK-101) in dogs with malignant melanoma demonstrates tolerable safety and early signs of biologic activity. Human ANK-101 is an IL-12- based anchored immunotherapy with IND submission planned for late 2023 BOSTON, MA, April...
by Anand Patadiya | Oct 2, 2024
August 7, 2023, CAMBRIDGE, MA – Ankyra Therapeutics, a pre-clinical biotechnology company developing targeted immune potentiating agents for the treatment of cancer, today announced the appointment of Robert V. Tighe., as chief scientific officer. He joined the team...
by Anand Patadiya | Oct 2, 2024
September 23, 2024 (Cambridge, MA) – Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings...
by Anand Patadiya | Sep 20, 2024
ANK-101 is a novel first-in-class anchored IL-12 immunotherapy designed for limited intratumoral delivery to increase immune cell infiltration into tumors, with potential to improve outcomes of patients treated with immune checkpoint inhibitors CAMBRIDGE, Mass. –...
